<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937738</url>
  </required_header>
  <id_info>
    <org_study_id>275</org_study_id>
    <nct_id>NCT04937738</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy in Gastric Cancer</brief_title>
  <acronym>PECORINO</acronym>
  <official_title>Evaluation of Pathological Response in Patient With Resectable Gastric Cancer and Perioperative Chemotherapy FLOT Versus XELOX; Phase 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ukrainian Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ukrainian Society of Clinical Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction&#xD;
      without previous therapy will be treated with one of two chemotherapy combinations before and&#xD;
      after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin&#xD;
      and Docetaxel (FLOT), the others Oxaliplatin and Capecitabin (XELOX). Main objective of the&#xD;
      study is histopathological regression rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      284 рatients with resectable (T1b-4 and/or N-/+, M0) adenocarcinoma of the stomach or the&#xD;
      esophagogastric junction without previous therapy will be included in this study. After&#xD;
      laparocopic staging patients will be randomized to receive preoperatively 4 cycles FLOT or 4&#xD;
      cycles XELOX followed by surgery. Subsequently another 4 cycles of FLOT or 4 cycles XELOX are&#xD;
      applicated. Primary endpoint is histopathological regression rate, secondary endpoints are&#xD;
      disease-free survival, perioperative morbidity and mortality, correlation between&#xD;
      pathological responce and disease-free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathological regression rate (Becker regression criteria)</measure>
    <time_frame>2 weeks after surgery</time_frame>
    <description>To determine histopathological regression rate after FLOT regimen compared to XELOX regimen in neoadjuvant settings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy toxicity profile</measure>
    <time_frame>at the end of XELOX cycle (each cycle is 21 days) and FLOT cycle (each cycle is 14 days)</time_frame>
    <description>To determine and compare toxicity profile in patients receiving XELOX or FLOT regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications rate</measure>
    <time_frame>up to 90th day after surgery</time_frame>
    <description>To determine surgical complication rate and profile after different types of regimens in neoadjuvant settings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year disease-free survival rate</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>To determine the efficacy of FLOT regimen compared to XELOX regimen during the first year after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between histopathological regression and disease-free survival</measure>
    <time_frame>2 years of follow-up after the last cycle of chemotherapy</time_frame>
    <description>To determine correlation between histopathological regression and disease-free survival in different chemotherapeutic settings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>5 year follow up after the last cycle of chemotherapy</time_frame>
    <description>To determine the efficacy of FLOT regimen compared to XELOX regimen by assessment of overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2, d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>2600 mg/m²d1 i.v. every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m² two times per day (BID), d1-14</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m² d1 i.v. every 3 weeks</description>
    <arm_group_label>XELOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cT1b-T4b (cT4b - invasion in diaphragm, parenchyma of liver, spleen, pancreas,&#xD;
             abdominal wall, small bowel, colon, distal part of splenic artery)&#xD;
&#xD;
          -  cN0-3&#xD;
&#xD;
          -  M0&#xD;
&#xD;
          -  Age: 18 - 80&#xD;
&#xD;
          -  ECOG: 0 - 1&#xD;
&#xD;
          -  Histological type: adenocarcinoma&#xD;
&#xD;
          -  Differentiation grade: G0 - G4&#xD;
&#xD;
          -  No previous surgery&#xD;
&#xD;
          -  No previous chemotherapy&#xD;
&#xD;
          -  No concomitant severe comorbidity&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cT1a, cT4b (invasion in truncus, hepatic artery, proximal part of splenic artery)&#xD;
&#xD;
          -  Presense of distant metastases&#xD;
&#xD;
          -  ECOG: 2 - 5&#xD;
&#xD;
          -  Age: &lt;18 and &gt;80&#xD;
&#xD;
          -  Severe concomitant comorbidity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Youryi Kondratskyi, PhD</last_name>
    <phone>+380673699224</phone>
    <email>ykondr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oleksii Dobrzhanskyi</last_name>
    <phone>+380638760185</phone>
    <email>alekseydobrzhanskiy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ukrainian Society of Clinical Oncology</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <last_name>Youryi Kondratskyi, PhD</last_name>
      <phone>+380673699224</phone>
      <email>ykondr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Viacheslav Kopetskyi</last_name>
      <phone>+380679953459</phone>
      <email>holerik@ukr.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perioperative chemotherapy</keyword>
  <keyword>pathological responce rate</keyword>
  <keyword>gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the initial publication every participant will recieve all the data to provide further data exploration.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after initial paper is published.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

